Biogen (BIIB) Gross Profit (2009 - 2026)

Biogen (BIIB) has reported Gross Profit for 18 consecutive years, with $1.8 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Gross Profit rose 0.84% year-over-year to $1.8 billion; the TTM figure through Mar 2026 stood at $7.5 billion (up 1.11% YoY), while the FY2025 annual figure was $7.5 billion, up 1.64% from the prior year.
• Gross Profit came in at $1.8 billion for Q1 2026 at Biogen, up from $1.8 billion in the prior quarter.
• The five-year high for Gross Profit was $2.4 billion in Q4 2022, with the low at $1.7 billion in Q1 2024.
• Average Gross Profit over 5 years is $2.0 billion, with a median of $1.9 billion recorded in 2023.
• Across the five-year window, Gross Profit declined 20.23% in 2023 and gained 6.34% in 2025, its largest moves.
• Year by year, Gross Profit stood at $2.4 billion in 2022, then decreased by 6.63% to $2.2 billion in 2023, then decreased by 15.8% to $1.9 billion in 2024, then retreated by 4.67% to $1.8 billion in 2025, then gained by 1.84% to $1.8 billion in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $1.8 billion, $1.8 billion, and $1.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.